Danish Robotics Company Kobots Open to Investors
27.9.2021 16:09:00 EEST | Business Wire | Press release
The people behind Kobots know that construction workers benefit from healthier, longer and more productive careers when robots are used to automate part of the workflow. Using the British crowdsourcing platform, Seedrs – which has no minimum investment requirement – Kobots is inviting everyone to invest in its robots to help the future of construction.
Sales of Kobots’ drywall cutting robot “Amigo” took off in 2020, and Kobots is raising 10 million Danish kroner (1.4 million Euro) to fund its international expansion. Amigo was developed by Danish carpenter Peter Hartvigsen to automatically cut drywall using measurements entered in a phone app.
Right now, Amigo is cutting 40,000 square metres of drywall used to construct the Danish highrise, Lighthouse.
“Amigo is perfect for Lighthouse because we have to cut so much drywall,” said Morten Kjaer, enterprise manager for Hustømrerne A/S, which works on LightHouse. “It allows us to keep a fast pace on the construction site.”
Dust reduction means big benefits to the work environment
Construction dust related lung disease takes the lives of 250 Danish workers annually.
Jonas Nymark hangs drywall at the Lighthouse site and he says the robot makes a huge difference in air quality.
“It's scary: we used to have at least three times as much dust in the air before we started using Amigo,” Nymark said. “I don’t want to go back to working in all that dust.”
Nobody is too busy to automize
Since its introduction in 2020, Kobot’s Amigo has cut enough drywall to cover 24 football fields, and it has preserved 34 tonnes of materials by saving and automatically remembering to use smaller pieces.
“Any company that’s gotten a demo of Amigo has either purchased or leased the robot,” said Peter Hartvigsen. “Kobots is positioned right there on the hockey stick growth chart where things are really going to take off.”
Collaboration with Velux and James Hardie Group
Among Kobots’ owners are some of the Danish robotics industry’s heavy hitters, like Niels Jul Jacobsen, the man behind Mobile Industrial Robots and Capra Robotics.
Construction material producers Velux and James Hardie Group are also working with Kobots.
This Seedrs crowdfunding round kicks off on Oct. 11, 2021, and you can reach it here or you can register for a private investment that opens on Sept. 29, here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005504/en/
Contact information
Press
Kobots’ PR Consultant
Malene Grouleff
+45-28915809
malene@grouleff.it
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Integrates AI into Client Portfolios – Informed by Agentic Technology, Controlled by the Client1.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced agentic trading through direct integration with Claude, one of the world's leading AI platforms. Available through the AI platform’s certified connector marketplace, the integration lets clients manage their accounts and access more than 170 global markets. "Interactive Brokers has used technology for over four decades to help investors make more informed decisions and interact more efficiently with markets," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Investors are increasingly using artificial intelligence to research markets, analyze information and generate ideas. We believe the next logical step is to allow clients to securely connect AI tools directly to their brokerage accounts — whether they want a simple conversational interface, deeper portfolio analysis or the ability to develop and execute sophisticated trading strategies.” Clients can link their existing IBKR account thro
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 16:01:00 EEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 16:00:00 EEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific
Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync ™ Series OSA 55101.6.2026 15:00:00 EEST | Press release
Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS support, encrypted and authenticated timing options and environmental protection enable operation in contested and GNSS-denied environments where trusted synchronization must be maintained. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601763766/en/ Oscilloquartz’s ruggedSync™ Series OSA 5510 delivers resilient, high-precision timing for mission-critical defense networks. “Our new ruggedSync™ Series OSA 5510 exte
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 15:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executive Vice President and Chief Regulatory and Quality Officer at Vertex. “With today’s FDA accepta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom